课题基金 / 基金详情

NV15496--R025 8310 VERSUS ROFERON A IN PATIENTS W/ CHRONIC HEPATITIS

NV15496--R025 8310 VERSUS ROFERON A IN PATIENTS W/ CHRONIC HEPATITIS
NV15496--R025 8310 与 ROFERON A 在慢性肝炎患者中的比较
批准号：
6263748
负责人：
KAREN L LINDSAY
金额：
$3.56万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6263748
关键词：
chronic disease /disorder clinical research hepatitis C hepatitis C virus human subject human therapy evaluation immunotherapy interferon alpha

项目摘要

项目成果

KAREN L LINDSAY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objective of this study is to evaluate the safety and efficacy of 135 and 180uh of PEG-IFN administered twice weekly compared to Roferon-A 3mu administered twice over a 48 week treatment period followed by a 24 week follow-up for patients with chronic hepatitis C.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: A RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE SAFETY OF LONG-TER
HCV RNA TESTING IN HALT-C SUSTAINED VIROLOGIC RESPONDERS
A RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE SAFETY OF LONG-TERM PEGYLATED A-A
ANCILLARY STUDY TO THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRR
海外基金